Chronic pain, chronic stress and depression: Coincidence or consequence?

Journal of Neuroendocrinology

Volumn 13, Issue 12, 2001, Pages 1009-1023

  Blackburn Munro, G ^a,b   Blackburn Munro, R E ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NEUROSEARCH A S   (Denmark)

^c H LUNDBECK A S   (Denmark)

Author keywords

Antidepressants; Hypothalamic pituitary adrenal (HPA) axis; Inflammation; Monoamines; Neuropathy

Indexed keywords

AMINOGLUTETHIMIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYTOKINE; FLUOXETINE; GLUCOCORTICOID; INTERFERON; INTERLEUKIN 1BETA; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MONOAMINE; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; HEMOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL STRESS; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CELL; SYMPTOMATOLOGY;

ANIMALS; CHRONIC DISEASE; DEPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PAIN; PITUITARY-ADRENAL SYSTEM; STRESS;

EID: 0035184459     PISSN: 09538194     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1331.2001.00727.x     Document Type: Review

References (162)

1. Antidepressants of the future - A critical assessment of the chemistry and pharmacology of novel antidepressants in development
2. Depressive disorders
3. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions
4. Patterns of ACTH secretagog secretion in response to psychological stimuli
5. Neurocircuitry of stress: Central control of the hypothalamo-pituitary-adrenocortical axis
6. The neuroendocrinology of depression and chronic stress
7. Regulation of pituitary ACTH secretion during chronic stress
8. Hypothalamo-pituitary-adrenal activity in experimental models of autoimmune-inflammatory disease
9. Inflammatory disease as a chronic stress
10. Differential effects of psychological and immunological challenge on the hypothalamo-pituitary-adrenal axis function in adjuvant-induced arthritis
11. Antidepressants and hypothalamic-pituitary-adrenocortical regulation
12. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?
13. Single stress induces long-lasting elevations in vasopressin mRNA levels in CRF hypophysiotrophic neurones, but repeated stress is required to modify AVP immunoreactivity
14. Regulation of corticotropin releasing hormone receptor messenger ribonucleic acid in the rat brain and pituitary by glucocorticoids and stress
15. Evidence for a specific role of vasopressin in sustaining pituitary-adrenocortical stress response in the rat
16. Desensitization of the hypothalamic-pituitary-adrenal axis following prolonged administration of corticotropin releasing hormone or vasopressin
17. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: Implications for stress adaptation
18. Patterns of adrenocorticotropin secretagog release in response to social interactions and various degrees of novelty
19. Repeated stress-induced activation of corticotropin-releasing factor neurons enhances vasopressin stores and colocalization with corticotropin-releasing factor in the median eminence of rats
20. Repeated stress enhances vasopressin in corticotropin-releasing factor neurons in the paraventricular nucleus
21. Regulatory changes in neuroendocrine stress-integrative circuitry produced by a variable stress paradigm
22. Stress down regulates corticosterone receptors in a site-specific manner in the brain
23. Pituitary adreno-cortical response to chronic intermittent stress
24. Loss of glucocorticoid fast feedback in depression
25. Serotonin receptor binding in a colony model of chronic social stress
26. Early postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content, and stress-induced corticosterone release in adult rats
27. Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation: From obesity to memory deficits
28. The glucocorticoid cascade hypothesis in man: Prolonged stress may cause permanent brain damage
29. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients
30. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis
31. Reduced corticotropin-releasing factor binding sites in the frontal cortex of suicide victims
32. Increased number of vasopressin and oxytocin expressing neurons in the paraventricular nucleus of the human hypothalamus in depression
33. Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls
34. Regulation of the glucocorticoid receptor in human lymphocytes
35. Repeated dexamethasone suppression test during depressive illness. Normalization of test result compared with clinical improvement
36. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression
37. 24-hour profiles of adrenocorticotropin, cortisol and growth hormone in major depressive illness: Effect of antidepressant treatment
38. The dexamethasone suppression test for melancholia
39. Adrenal gland enlargement in major depression
40. Pituitary size in depression
41. Neuroendocrine mechanisms and the precipitation of depression by life events
42. A prospective study of response to stressful life events in initially healthy elders
43. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures
44. Chronic treatment of rats with the antidepressant amitryptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system
45. Antidepressant and anxiolytic activities of tianeptine; an overview of clinical trials
46. Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy
47. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated
48. Stress-induced analgesia: Adaptive pain suppression
49. The induction of pain: An integrative review
50. Neuronal plasticity: Increasing the gain in pain
51. Peripheral pain mechanisms
52. Ions in the fire. Recent ion-channel research and approaches to pain therapy
53. Impaired nociception and pain sensation in mice lacking the capsaicin receptor
54. Pharmacology of chronic pain
55. The role of corticotropin-releasing factor in pain and analgesia
56. The effect of noradrenaline, angiotensin II and vasopressin on blood flow and sensitivity to heat in capsaicin-treated skin
57. Anti-inflammatory actions of steroids: Molecular mechanisms
58. Second messengers, the substantia gelatinosa and injury-induced persistent pain
59. Sex steroid regulation of the inflammatory response: Sympathoadrenal dependence in the female rat
60. The molecular pathophysiology of pain: Abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons
61. Axotomy upregulates the anterograde transport and expression of brain-derived neurotrophic factor by sensory neurones
62. Building blocks of pain: The regulation of key molecules in spinal sensory neurones during development and following peripheral axotomy
63. Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain
64. Messenger plasticity in primary sensory neurons following axotomy and its functional implications
65. Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumour necrosis factor alpha
66. 2 in a model of acute arthritis is accompanied by an up-regulation of cyclo-oxygenase-2 in the spinal cord
67. VIP and PACAP: Very important in pain?
68. Antinociception vs. motor effects of intrathecal vasopressin as measured by four pain tests
69. Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy
70. Changes in brain-derived neurotrophic factor immunoreactivity in rat dorsal root ganglia, spinal cord, and gracile nuclei following cut or crush injuries
71. C: Adrenergic receptor immunoreactivity in the rat spinal cord
72. Complimentary distribution of receptors for neurotensin and NPY in small neurons in rat lumbar DRGs and regulation of the receptors and peptides after peripheral axotomy
73. B receptor binding in the spinal cord following peripheral inflammation or neuroectomy
74. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
75. Brain corticosteroid receptor balance and homeostatic control
76. Interleukins-1 and -6 stimulate the release of CRH-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway
77. Role of tachykinins in the regulation of the hypothalamo-pituitary-adrenal axis
78. Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis
79. Interaction between GABAergic neurotransmission and rat hypothalamic corticotropin-releasing hormone secretion in vitro
80. Nitric oxide stimulates ACTH secretion and the transcription of the genes encoding for NGFI-B, corticotrophin-releasing factor, corticotrophin-releasing factor receptor type 1, and vasopressin in the hypothalamus of the intact rat
81. Role of VIP, PACAP and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis
82. Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone
83. Neuroendocrine markers. Role in the development of antidepressants
84. Role of neuromedins in the regulation of adrenocortical function
85. Indomethacin attenuates oxytocin and hypothalamic-pituitary-adrenal axis responses to systemic interleukin-1 beta
86. Effects of cholecystokinin on the pituitary-adrenal axis of rats with intact or regenerating adrenal glands
87. The effects of oestrogen and progesterone on corticotropin-releasing hormone and arginine vasopressin messenger ribonucleic acid levels in the paraventricular nucleus and supraoptic nucleus of the rhesus monkey
88. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons
89. Differential properties of tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels in rat dorsal root ganglion neurons
90. A synaptic model of memory: Long-term potentiation in the hippocampus
91. Central changes in primary afferent fibres following peripheral nerve lesions
92. Collateral sprouting of injured primary afferent A-fibers into the superficial dorsal horn of the adult rat spinal cord after topical capsaicin treatment to the sciatic nerve
93. Colocalization of Fos- and glucocorticoid receptor immunoreactivities is present only in a very restricted population of dorsal horn neurons of the rat after nociceptive stimulation
94. Glucocorticoid inhibition of neuropathic hyperalgesia and spinal Fos expression
95. From medulla to thalamus. Central nervous system mechanisms of pain modulation
96. Thalamic processing of sensory-discriminative and affective-motivational dimensions of pain
97. Interconnections between the neuroendocrine hypothalamus and the central autonomic system
98. Central nervous system mechanisms of pain modulation
99. Forebrain mechanisms of nociception and pain: Analysis through imaging
100. Central mechanisms of pain modulation
101. Serotonin (5-HT) and pain: A reappraisal of its role in the light of receptor multiplicity
102. Supraspinal contributions to hyperalgesia
103. The role of corticosteroids in analgesic effect caused by stimulation of the periaqueductal gray matter of the midbrain
104. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain - Evidence for selective increases in glucocorticoid receptor immunoreactivity in the 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla
105. Reorganization of somatosensory cortex after nerve and spinal cord injury
106. Pituitary-adrenocortical responses to persistent noxious stimuli in the awake rat: Endogenous corticosterone does not reduce nociception in the formalin test
107. Chronic pain and fatigue syndromes: Overlapping clinical and neuroendocrine features and potential pathogenic mechanisms
108. Function of the hypothalamic adrenal axis in patients with fibromyalgia syndrome undergoing mud-pack treatment
109. Glucocorticoid receptors, fibromyalgia and low back pain
110. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6 - A pilot study in fibromyalgia
111. The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome
112. Depression and the experience of chronic back pain: A study of related variables and age differences
113. Hypothalamic-pituitary-mediated immunomodulation: Arginine vasopressin is a neuroendocrine immune mediator
114. The neuroendocrine immune basis of rheumatic diseases
115. Negative affect and pain in arthritis
116. Glucocorticoids and the immune system
117. The relationship between self-reported pain and sociodemographic variables, anxiety, and depressive symptoms in rheumatoid arthritis
118. Pain modulation
119. Clinical aspects of depression in chronic pain patients
120. Chronic pain-associated depression. Antecedent or consequence of chronic pain. A review
121. Review article on the relationship between chronic pain and depression when there is no organic lesion
122. Alternative diagnostic criteria for major depressive disorder in patients with chronic pain
123. A systematic review of antidepressants in neuropathic pain
124. The analgesic effects of selective serotonin reuptake inhibitors
125. Antidepressant-induced analgesia in chronic non-malignant pain. A meta-analysis of 39 placebo-controlled studies
126. Physiological and behavioural responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses?
127. Interleukin 1β and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue
128. Physiology and pharmacology of corticotropin-releasing factor
129. Spinal cord-projecting vasopressinergic neurons in the rat paraventricular hypothalamus
130. Central Interleukin-1 receptors as mediators of sickness
131. Somnogenic cytokines and models concerning their effects on sleep
132. Effect of endotoxin and IL-1 (on CRF and prostaglandin release by rat brainstem slices)
133. Effect of IL-1 (on hippocampal serotonergic neurotransmission, behavioural activity and free corticosterone levels: An in vivo microdialysis study
134. Cytokine production in major depressed patients before and after clomipramine treatment
135. Regulation of cytokine gene expression in the central nervous system by glucocorticoids: Mechanisms and functional consequences
136. Induction of cytokine receptors by glucocorticoids: Functional and pathological significance
137. Nociceptive and inflammatory effects of subcutaneous TNFα
138. Neuropathic pain from an experimental neuritis of the rat sciatic nerve
139. Differential temporal expression of mRNAs for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and their receptors (CNTFRα, LIFRβ, IL-R6α and gp130) in injured peripheral nerves
140. New insights into the pathogenesis and treatment of rheumatoid arthritis
141. Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: Potential role of IL-6 in neuropathic pain
142. Acute peripheral inflammation induces moderate glial activation and spinal IL-1β expression that correlates with pain behaviour in the rat
143. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures
144. Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injections
145. Neural mechanisms involved in the corticosteroid feedback effects on the hypothalamo-pituitary-adrenocortical axis
146. Hypothalamic norepinephrine mediates limbic effects on adrenocortical secretion
147. Contribution of the ventral subiculum to inhibitory regulation of the hypothalamo-pituitary-adrenocortical axis
148. The involvement of serotonin in regulation of pituitary-adrenocortical function
149. Paraventricular nucleus serotonin mediates neurally stimulated adrenocortical secretion
150. Age-dependent loss of corticosterone modulation of central serotonin 5-HT1A receptor binding sites
151. The role of descending noradrenergic and serotonergic pathways in the modulation of nociception: Focus on receptor multiplicity
152. Rapid sprouting of sympathetic axons in dorsal root ganglia of rats with a chronic constriction injury
153. Adrenoceptor subtype mediating sympathetic-sensory coupling in injured sensory neurons
154. 2-adrenergic receptor subtypes in rat dorsal root and superior cervical ganglion neurons
155. Central tachykinins: Mediators of defence reaction and stress reactions
156. Reduction of substance P after chronic antidepressants treatment in the striatum, substancia nigra and amygdala of the rat
157. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
158. The how and why of chronic pain states and the what of new analgesia therapies
159. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function
160. Lesion of the bulbospinal noradrenergic pathways blocks desipiramine-induced inhibition of the C-fiber evoked nociceptive reflex in rats